Living Cell Technologies (ASX: LCT), has today released results of
pre-clinical studies demonstrating that its specialised therapy
protects nerve cells in the brain from damage caused by conditions
similar to Huntington's disease.
Animals receiving LCT's treatment, NeurotrophinCell, showed 86 per
cent less damage to the brain and showed dramatically improved use of
their limbs. Australia:

This is the first time that technology of this kind has been proven
in a
controlled pre-clinical setting to prevent the degeneration of the
brain due to Huntington's disease-like conditions. The details and
data are to be presented at the Society for Neuroscience annual
conference in San Diego this weekend and published in NeuroReport in
November.

Huntington's disease is a devastating and fatal neurodegenerative
condition that can be diagnosed very early in life, before symptoms
appear, but for which there is no cure or intervention strategy
available.
"These findings have major implications for enabling treatment of
human
neurodegenerative diseases such as Huntington's and stroke," said Dr.
Dwaine Emerich, VP of Research at LCT BioPharma Inc1 and co-author of
the paper detailing the findings.

"What we have done is successfully implant new choroid plexus cells
(the cells that produce cerebral spinal fluid and a number of factors
important for the health and survival of the brain) thereby
protecting specific areas of the brain from damage" continued Dr.
Emerich.
In LCT's proprietary product, NeurotrophinCell, the choroid plexus
cells are encapsulated in a clear capsule derived from algae. This
encapsulation hides the cells from the patient's immune system yet
allows the cells to receive nutrients and chemical signals necessary
for functionality and survival."

"NeurotrophinCell has effectively shown the ability of LCT's
technology, to protect brain tissue that would otherwise die,
potentially forestalling or
preventing the debilitating consequences of this disease," said Alfred
Vasconcellos, LCT BioPharma's CEO.

About Living Cell Technologies
www.lct.com.au
LCT is an ASX listed biotechnology company (ASX:LCT).
Living Cell Technologies Ltd (LCT) began its business to develop and
commercialise cell therapies for the treatment of a wide variety of
diseases in 1987. The company is headquartered in Adelaide, South
Australia with operating companies in New Zealand and Rhode Island,
US.

LCT's technology has potential application for the treatment of
conditions caused by a deficiency of specific cell function. The
company has three products under development -
NeurotrophinCell for Huntington's, Fac8Cell for haemophilia and
DiabeCell for diabetes. NeurotrophinCell Cells of the choroid plexus
produce the fluid and growth factors that surround and bathe the
brain. Findings published in NeuroReport October 2004 detailed the
transplant of encapsulated cells into an animal model of Huntington's
disease. These pre-clinical studies demonstrated that placement of
NeurotrophinCell near endangered nerve tissue will deliver
therapeutic factors which protect cells that would otherwise die.

Huntington's disease
Huntington's disease is an inherited brain disorder that affects both
body and mind. Usually diagnosed between ages 35 and 50, Huntington's
affects about 1 in 10,000 people and has no
cure or treatment. Children with a parent with Huntington's have a
50% chance of inheriting
the disease.

Media Information Company Information -
AUS
US
NZ
Rebecca Christie
Buchan
Tel: +612 9293 2836
Mobile +61 417382391
rchristie@...

Roger Coats
COO - LCT Ltd
Tel: +618 8179 2874
Fax: +618 8179 2885
r.coats@...

Dr. Alfred Vasconcellos
CEO - LCT BioPharma Inc
Tel: +1 401-821-3500
Fax: +1 401-823-0466
a.vasconcellos@...

Prof Bob Elliott
Medical Director
LCT Ltd
Tel: +64 9276 2690
Fax: +64 9276 2691
r.elliott@...